The DOI matches its Crossref record.
Review of pyronaridine anti-malarial properties and product characteristics
Open accessAbstract
Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years for the treatment of malaria. Pyronaridine has high potency against Plasmodium falciparum, including chloroquine-resistant strains. Studies in various animal models have shown pyronaridine to be effective against strains resistant to other anti-malarials, including chloroquine. Resistance to pyronaridine appears to emerge slowly and is further retarded when pyronaridine is used in combination with other anti-malarials, in particular, artesunate. Pyronaridine toxicity is generally less than that of chloroquine, though evidence of embryotoxicity in rodents suggests use with caution in pregnancy. Clinical pharmacokinetic data for pyronaridine indicates an elimination T1/2 of 13.2 and 9.6 days, respectively, in adults and children with acute uncomplicated falciparum and vivax malaria in artemisinin-combination therapy. Clinical data for mono or combined pyronaridine therapy show excellent anti-malarial effects against P. falciparum and studies of combination therapy also show promise against Plasmodium vivax. Pyronaridine has been developed as a fixed dose combination therapy, in a 3:1 ratio, with artesunate for the treatment of acute uncomplicated P. falciparum malaria and blood stage P. vivax malaria with the name of Pyramax® and has received Positive Opinion by European Medicines Agency under the Article 58 procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The past, present and future of anti-malarial medicines
Tse, E. G., Korsik, M., & Todd, M. H. (2019) · Malaria Journal · doi:10.1186/s12936-019-2724-z · Cited by 471
Mannich bases in medicinal chemistry and drug design
Roman, G. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.076 · Cited by 357
Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery
Ekins, S., Lage de Siqueira-Neto, J., McCall, L.-I., Sarker, M., Yadav, M., Ponder, E. L., Kallel, E. A., Kellar, D., Chen, S., Arkin, M., et al. (2015) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0003878 · Cited by 93
Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads
Anantpadma, M., Lane, T., Zorn, K. M., Lingerfelt, M. A., Clark, A. M., Freundlich, J. S., Davey, R. A., Madrid, P. B., & Ekins, S. (2019) · ACS Omega · doi:10.1021/acsomega.8b02948 · Cited by 54
Metadata
- Authors
- Croft, S. L., Duparc, S., Arbe-Barnes, S. J., Craft, J. C., Shin, C.-S., Fleckenstein, L., Borghini-Fuhrer, I., & Rim, H.-J.
- Venue
- Malaria Journal
- Published
- 2012-08-09
- Volume
- 11
- Issue
- 1
- Pages
- 270-270
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W2139242164
- Cited by
- 159
- References
- 0
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of pyronaridine anti-malarial properties and product characteristics. https://app.cochat.ai/papers/10.1186/1475-2875-11-270
- The paper
- Croft, S. L., Duparc, S., Arbe-Barnes, S. J., Craft, J. C., Shin, C.-S., Fleckenstein, L., Borghini-Fuhrer, I., & Rim, H.-J. (2012). Review of pyronaridine anti-malarial properties and product characteristics. Malaria Journal. https://doi.org/10.1186/1475-2875-11-270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.